Shares of MIRA Pharmaceuticals nearly tripled in value since July 19 on news about the continued preclinical success of its investigational drug candidate, Ketamir-2. The newly released data from in vitro studies elucidates a potential mechanism underlying Ketamir-2’s superior oral absorption and ability to penetrate the blood-brain barrier more effectively than traditional ketamine. Improved penetration into target tissues would allow for lower doses of Ketamir-2 to achieve therapeutic effects.
‍

MIRA Pharmaceuticals has advanced its two preclinical assets, Ketamir-2 and MIRA-55, through preclinical testing, generating encouraging results. We summarize recent company news below.

‍